| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Outline of Final Research Achievements |
Urothelial carcinomas (UCs) are the eighth-most lethal cancer in men in the United States. The standard examinations are performed, involving urine cytology, urinary tract imaging and cystoscopy, which are powerful diagnostic tools for UCs. However, Urine cytology is not reliable in patients with early stage UCs, including UTUC, and it is difficult to visualise small tumors via imaging modalities, such as ultrasound or computed tomography. Thus, more sensitive and non-invasive biomarkers, such as serum-based biomarkers, to avoid under-detection in patients at high risk of UCs is required. In the present study, we performed N-glycomics of serum Igs fractions between healthy volunteers (HVs), prostate cancer (PC) and UCs patients to identify the UC-specific aberrant N-glycosylated Igs. Furthermore, for clinical applications, we established a diagnostic NGScore (dNGScore) based on a combination of five N-glycans of Igs associated with detection of UCs.
|
